These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 35383486)

  • 61. Contrast-enhanced US with Perfluorobutane(Sonazoid) used as a surveillance test for Hepatocellular Carcinoma (HCC) in Cirrhosis (SCAN): an exploratory cross-sectional study for a diagnostic trial.
    Park JH; Park MS; Lee SJ; Jeong WK; Lee JY; Park MJ; Han K; Nam CM; Park SH; Lee KH
    BMC Cancer; 2017 Apr; 17(1):279. PubMed ID: 28420329
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pathological considerations of CEUS LI-RADS: correlation with fibrosis stage and tumour histological grade.
    Cheng MQ; Hu HT; Huang H; Pan JM; Xian MF; Huang Y; Kuang M; Xie XY; Li W; Wang W; Lu MD
    Eur Radiol; 2021 Aug; 31(8):5680-5688. PubMed ID: 33502556
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Limitations Associated With Assessing Liver Ultrasound Quality Using US LI-RADS Visualization Score When Utilizing Acquired Images.
    Kutaiba N; Ardalan ZS
    Clin Gastroenterol Hepatol; 2022 Jul; 20(7):1617-1618. PubMed ID: 34358717
    [No Abstract]   [Full Text] [Related]  

  • 64. Noncontrast magnetic resonance imaging versus ultrasonography for hepatocellular carcinoma surveillance (MIRACLE-HCC): study protocol for a prospective randomized trial.
    An C; Kim DY; Choi JY; Han KH; Roh YH; Kim MJ
    BMC Cancer; 2018 Sep; 18(1):915. PubMed ID: 30249190
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cirrhotic liver: What's that nodule? The LI-RADS approach.
    Shah A; Tang A; Santillan C; Sirlin C
    J Magn Reson Imaging; 2016 Feb; 43(2):281-94. PubMed ID: 25996905
    [TBL] [Abstract][Full Text] [Related]  

  • 66. LI-RADS: Past, Present, and Future, From the
    Marks RM; Masch WR; Chernyak V
    AJR Am J Roentgenol; 2021 Feb; 216(2):295-304. PubMed ID: 33052720
    [TBL] [Abstract][Full Text] [Related]  

  • 67. CEUS LI-RADS: algorithm, implementation, and key differences from CT/MRI.
    Wilson SR; Lyshchik A; Piscaglia F; Cosgrove D; Jang HJ; Sirlin C; Dietrich CF; Kim TK; Willmann JK; Kono Y
    Abdom Radiol (NY); 2018 Jan; 43(1):127-142. PubMed ID: 28819825
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis.
    Del Poggio P; Olmi S; Ciccarese F; Di Marco M; Rapaccini GL; Benvegnù L; Borzio F; Farinati F; Zoli M; Giannini EG; Caturelli E; Chiaramonte M; Trevisani F;
    Clin Gastroenterol Hepatol; 2014 Nov; 12(11):1927-33.e2. PubMed ID: 24582947
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Validation of Liver Imaging Reporting and Data System 2017 (LI-RADS) Criteria for Imaging Diagnosis of Hepatocellular Carcinoma.
    Kierans AS; Makkar J; Guniganti P; Cornman-Homonoff J; Lee MJ; Pittman M; Askin G; Hecht EM
    J Magn Reson Imaging; 2019 Jun; 49(7):e205-e215. PubMed ID: 30257054
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Contrast-Enhanced Ultrasound Algorithms (CEUS-LIRADS/ESCULAP) for the Noninvasive Diagnosis of Hepatocellular Carcinoma - A Prospective Multicenter DEGUM Study.
    Schellhaas B; Bernatik T; Bohle W; Borowitzka F; Chang J; Dietrich CF; Dirks K; Donoval R; Drube K; Friedrich-Rust M; Gall C; Gittinger F; Gutermann M; Haenle MM; von Herbay A; Ho CH; Hochdoerffer R; Hoffmann T; Hüttig M; Janson C; Jung EM; Jung N; Karlas T; Klinger C; Kornmehl A; Kratzer W; Krug S; Kunze G; Leitlein J; Link A; Lottspeich C; Marano A; Mauch M; Moleda L; Neesse A; Petzold G; Potthoff A; Praktiknjo M; Rösner KD; Schanz S; Schultheiß M; Sivanathan V; Stock J; Thomsen T; Vogelpohl J; Vogt C; Wagner S; Wiegard C; Wiesinger I; Will U; Ziesch M; Zimmermann P; Strobel D
    Ultraschall Med; 2021 Apr; 42(2):178-186. PubMed ID: 32663881
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Differentiation of intrahepatic cholangiocarcinoma from hepatocellular carcinoma in high-risk patients: A predictive model using contrast-enhanced ultrasound.
    Chen LD; Ruan SM; Liang JY; Yang Z; Shen SL; Huang Y; Li W; Wang Z; Xie XY; Lu MD; Kuang M; Wang W
    World J Gastroenterol; 2018 Sep; 24(33):3786-3798. PubMed ID: 30197484
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Ultrasound surveillance for hepatocellular carcinoma of at-risk patients in Ramathibodi Hospital.
    Prapruttam D; Suksai J; Kitiyakara T; Phongkitkarun S
    J Med Assoc Thai; 2014 Nov; 97(11):1199-208. PubMed ID: 25675686
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Evaluation of an abbreviated screening MRI protocol for patients at risk for hepatocellular carcinoma.
    Lee JY; Huo EJ; Weinstein S; Santos C; Monto A; Corvera CU; Yee J; Hope TA
    Abdom Radiol (NY); 2018 Jul; 43(7):1627-1633. PubMed ID: 29018942
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Does quantitative assessment of arterial phase hyperenhancement and washout improve LI-RADS v2018-based classification of liver lesions?
    Stocker D; Becker AS; Barth BK; Skawran S; Kaniewska M; Fischer MA; Donati O; Reiner CS
    Eur Radiol; 2020 May; 30(5):2922-2933. PubMed ID: 32020398
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Diagnostic Accuracy of Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) for Differentiating Between Hepatocellular Carcinoma and Other Hepatic Malignancies in High-Risk Patients: A Meta-Analysis.
    Li J; Yang L; Ma L; Lu Q; Luo Y
    Ultraschall Med; 2021 Apr; 42(2):187-193. PubMed ID: 33307595
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Diagnostic Performance of 2018 KLCA-NCC Practice Guideline for Hepatocellular Carcinoma on Gadoxetic Acid-Enhanced MRI in Patients with Chronic Hepatitis B or Cirrhosis: Comparison with LI-RADS Version 2018.
    Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
    Korean J Radiol; 2021 Jul; 22(7):1066-1076. PubMed ID: 33739633
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017.
    Ren AH; Zhao PF; Yang DW; Du JB; Wang ZC; Yang ZH
    J Magn Reson Imaging; 2019 Sep; 50(3):746-755. PubMed ID: 30648327
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Contrast-enhanced ultrasound: Liver Imaging Reporting and Data System (CEUS LI-RADS)].
    Dietrich CF; Potthoff A; Helmberger T; Ignee A; Willmann JK;
    Z Gastroenterol; 2018 May; 56(5):499-506. PubMed ID: 29734449
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Contrast-enhanced ultrasound for screening hepatocellular carcinoma: an implemented program at a semi-rural academic center.
    Motz VL; White R; Lee R; Vu T; Shin B; McGillen KL
    Abdom Radiol (NY); 2021 Sep; 46(9):4170-4177. PubMed ID: 33956204
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Analysis of comparative performance of CEUS and CECT/MR LI-RADS classification: Can CEUS dichotomize LI-RADS indeterminate lesions on CT or MRI?
    Tan Z; Teoh WC; Wong KM; Wansaicheong GK; Sandrasegaran K
    Clin Imaging; 2020 Jun; 62():63-68. PubMed ID: 32070868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.